Journal article
Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization
JH Wang, CL Tseng, FL Lin, J Chen, EH Hsieh, S Lama, YF Chuang, S Kumar, L Zhu, MB McGuinness, J Hernandez, L Tu, PY Wang, GS Liu
Theranostics | Published : 2022
DOI: 10.7150/thno.65098
Abstract
Rationale: Corneal neovascularization (CoNV) is a severe complication of various types of corneal diseases, that leads to permanent visual impairment. Current treatments for CoNV, such as steroids or anti-vascular endothelial growth factor (VEGF) agents, are argued over their therapeutic efficacy and adverse effects. Here, we demonstrate that transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) plays an important role in the pathogenesis of CoNV. Methods: Angiogenic activities were assessed in ex vivo and in vitro models subjected to TAK1 inhibition by 5Z-7-oxozeaenol, a selective inhibitor of TAK1. RNA-Seq was used to examine pathways that could be potentially affected by TAK1 inh..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by grants from the National Health and Medical Research Council of Australia (1185600) , the National Natural Science Foundation of China (82000902; China) , the Shenzhen Key Laboratory of Biomimetic Materials and Cellular Immunomodulation (ZDSYS20190902093409851) , the Integrated Research Grant in Health and Medical Sciences from the National Health Research Institute, Taiwan (NHRI-EX110-10933SI) and the Ministry of Science and Technology, Taiwan (MOST109-2221-E-038-008, 110-2314-B-038-044-MY2) . The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian Government.